Gail Roboz, MD

Dr Gabriel Mannis from Stanford University and Dr Gail Roboz from Weill Cornell Medicine discussed the evolving treatment landscape for relapsed/refractory NPM1-mutant acute myeloid leukemia.

Gail Roboz, MD, discusses the use of FLT3 inhibitors as treatment of patients with acute myeloid leukemia, which can be a heterogenous and difficult-to-treat disease. There is a lot of optimism for new drugs and targets in AML, but the disease itself remains tough to treat, according to Roboz.